Cachofeiro V, Maeso R, Rodrigo E, Navarro J, Ruilope L M, Lahera V
Department of Physiology, Complutense University, Medical School, Madrid, Spain.
Hypertension. 1995 Aug;26(2):236-43. doi: 10.1161/01.hyp.26.2.236.
We investigated the role of endogenous nitric oxide, kinins, and prostaglandins in the vasodepressor and renal excretory effects of the angiotensin II receptor antagonist losartan and the angiotensin-converting enzyme inhibitor ramipril administered for 1 week to spontaneously hypertensive rats. To this end, either losartan (10 mg/kg per day) or ramipril (2.5 mg/kg per day) was administered in drinking water with or without simultaneous administration of (1) the nitric oxide synthesis inhibitor Ng-nitro-L-arginine methyl ester (L-NAME, 6 mg/kg per day), (2) the cyclooxygenase inhibitor indomethacin (5 mg/kg per day), (3) the bradykinin B2 receptor antagonist Hoe 140 (0.5 mg/kg per day SC), or (4) L-NAME plus indomethacin. Both losartan and ramipril significantly reduced blood pressure as measured by the tail-cuff method. L-NAME increased blood pressure when administered solely or in combination with losartan. However, L-NAME attenuated the hypotensive effect of ramipril. Indomethacin did not affect blood pressure but it reduced the antihypertensive action of losartan and ramipril. Indomethacin administration did not potentiate the increase in blood pressure induced by L-NAME. However, the concurrent administration of both inhibitors almost totally blunted the vasodepressor action of ramipril. By contrast, losartan administration in the presence of L-NAME and indomethacin increased blood pressure to a level similar to that after losartan plus L-NAME. Hoe 140 did not modify either blood pressure or the hypotensive effects of losartan or ramipril. Increases in diuresis and water intake were observed during ramipril administration. Both effects were blunted only with the concurrent administration of L-NAME and indomethacin.(ABSTRACT TRUNCATED AT 250 WORDS)
我们研究了内源性一氧化氮、激肽和前列腺素在血管紧张素II受体拮抗剂氯沙坦和血管紧张素转换酶抑制剂雷米普利对自发性高血压大鼠进行为期1周给药的血管降压和肾脏排泄作用中的作用。为此,在饮用水中给予氯沙坦(每天10毫克/千克)或雷米普利(每天2.5毫克/千克),同时给予或不给予以下药物:(1)一氧化氮合成抑制剂Nω-硝基-L-精氨酸甲酯(L-NAME,每天6毫克/千克);(2)环氧化酶抑制剂吲哚美辛(每天5毫克/千克);(3)缓激肽B2受体拮抗剂Hoe 140(每天0.5毫克/千克,皮下注射);或(4)L-NAME加吲哚美辛。通过尾套法测量,氯沙坦和雷米普利均显著降低了血压。单独给予L-NAME或与氯沙坦联合给予时,L-NAME会升高血压。然而,L-NAME减弱了雷米普利的降压作用。吲哚美辛不影响血压,但它降低了氯沙坦和雷米普利的降压作用。给予吲哚美辛不会增强L-NAME引起的血压升高。然而,两种抑制剂同时给药几乎完全消除了雷米普利的血管降压作用。相比之下,在L-NAME和吲哚美辛存在的情况下给予氯沙坦会使血压升高到与氯沙坦加L-NAME后相似的水平。Hoe 140既不改变血压,也不改变氯沙坦或雷米普利的降压作用。在给予雷米普利期间观察到利尿和水摄入量增加。仅在同时给予L-NAME和吲哚美辛时,这两种作用才减弱。(摘要截断于250字)